Amazon’s Extra Strength Acetaminophen Is Recalled: 112,932 Bottles in Seven Lots, Started September 18, 2026 Over Discolored Tablets — and the FDA Still Hasn’t Said How Serious It Is

If you have a bottle of Amazon’s house-brand Extra Strength Acetaminophen 500 mg caplets at home, look at the lot number and expiration date printed on the label. Seven lots are recalled. The FDA’s own record gives the reason in one line: “Discoloration: consumer complaints received for discolored tablets.” The tablets are supposed to be white to off-white.

• 200-count bottles (NDC 72288-692-20): lot ACD125040A, exp. 9/30/2027 — 14,640 bottles. One outlet, WSLS, prints this lot without the final “A” as ACD125040.
• 500-count bottles (NDC 72288-692-50): lots ACD124036A and ACD124030A (exp. 9/30/2027), ACD124042A (exp. 10/31/2027), ACD124048B (exp. 11/30/2027) and ACD125010A (exp. 2/29/2028) — 90,456 bottles.
• 1,000-count bottles (NDC 72288-692-01): lot ACD124048A, exp. 11/30/2027 — 7,836 bottles.

Bottles from other lots are not part of the recall. The 1,000-count entry is the one we could read directly in the FDA’s openFDA data; the 200- and 500-count lots and the 112,932 total come from Fox Business and Medical Daily, which reported the FDA Enforcement Report listing. The FDA record names the recalling firm as Aurobindo Pharma USA Inc. of East Windsor, NJ, and the distributor as Amazon.com Services LLC of Seattle; the label says “Made in India.”

As of October 14, 2026, the recall is listed as “Not Yet Classified.” That matters, because the class is how the FDA ranks the risk. In the agency’s own definitions, a Class I recall is one where there is “a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death”; Class II means the product “may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote”; Class III means it is “not likely to cause adverse health consequences.”

Neither Aurobindo nor the FDA has publicly explained what caused the color change, and Fox Business noted that the agency “did not describe any specific health risks or say whether any injuries have been reported.” There is one reference point. In May 2025 the same company recalled 4,608 bottles of Amazon-distributed 325 mg acetaminophen for the same kind of problem — “tablet discoloration (brown surface on tablets)” — and the FDA placed that recall in Class II. That is a precedent, not a prediction.

Practical steps: stop using a bottle that matches the list. If you took tablets from it and feel unwell, call a pharmacist or your doctor. Problems can be reported to the FDA’s MedWatch program, which takes reports from “health professionals, patients and consumers” for prescription and over-the-counter medicines.

A recall is not a lawsuit, and nobody gets a check because a recall exists. The FDA describes recalls as “actions taken by a firm to remove a product from the market,” carried out “on a firm’s own initiative, by FDA request, or by FDA order.” This one is marked “Voluntary: Firm initiated.” That is also the documented part of the answer to “Who pays for product recalls?” — the recalling company runs the recall; how Aurobindo and Amazon split the cost is not public.

What you can get is your money back for the bottle. Medical Daily advises that shoppers “can contact Amazon customer service about returns or refunds,” and that keeping the bottle and order details helps. There is no claim form, no deadline and no settlement fund connected to this recall as of October 14, 2026, and we found no court case tied to it; our check of the federal docket search returned no usable result, so we cannot rule out that one is filed later. If one is, it would be a separate process with its own notice.

If you bought generic prescription drugs over the years, there is a different, real settlement with a deadline: the generic-drug price-fixing settlements with Sandoz, Sun and Taro (see our related coverage below). That has nothing to do with this recall.

The recall is real: it is in the FDA’s enforcement data as event 99934, with the lots, bottle counts and reason listed above. The FDA record says the company’s first notification went out by “Letter.” A genuine recall notice tells you to stop using the product and how to return it or get a refund. It does not ask you to pay a fee, to give a bank card number to “release” a payment, or to sign up for a settlement. Anything that does is not part of this recall. If you are unsure, skip the link in a message and go straight to your Amazon order history or Amazon customer service, and check the lot number on the bottle yourself.

The question people ask most is “What medicine has a recall on it?” The FDA’s openFDA drug enforcement data shows 93 entries with report dates between September 2 and October 7, 2026 — by our count 8 in Class I, 76 in Class II, 7 in Class III and 2 not yet classified, spread over 47 recall events. A recall applies only to the listed lots. Highlights for people who take pills at home:

• Trazodone 50 mg (Teva): 175,392 bottles, “Presence of Foreign Tablets/Capsules,” initiated August 24, Class II.
• Thyroid Tablets 30 mg (1/2 grain) (Vitruvias Therapeutics): 1,955 bottles, “Superpotent Drug,” Class I — the most serious category.
• Levothyroxine (Accord Healthcare): many strengths from 25 mcg to 300 mcg, “Subpotent Drug,” initiated August 6, Class II.
• Prasugrel 10 mg (Mylan): 47,662 bottles, failed dissolution at 18-month stability testing, Class II.
• Chlorthalidone 25 mg (Inventia Healthcare): 13,567 bottles, failed dissolution, initiated September 3, Class II.
• Olanzapine 5 mg (Macleods): 22,032 bottles, impurities above specification, Class III.
• Paroxetine extended-release 37.5 mg (Apotex) and ranolazine extended-release 1000 mg (Ajanta): failed dissolution, Class II, both in the October 7 report.
• Clear Eyes Redness Relief eye drops: 2,356,248 bottles, “Lack of Assurance of Sterility,” initiated September 15, Class II.

Your pharmacist can tell you whether the lot in your bottle is affected. Do not stop a prescription medicine on your own because of a recall headline — ask first.

Metoprolol, the blood-pressure and heart drug, has had several separate recalls, none in the September–October 2026 window above. The most recent ones in the FDA’s data are for “Failed Dissolution Specifications” — meaning the extended-release tablets did not release the drug at the tested rate: Ascend Laboratories recalled 17,304 100-count bottles of metoprolol succinate ER 25 mg (lot 25140859, exp. January 2027), initiated April 27, 2026, and Teva recalled metoprolol succinate ER 25, 50, 100 and 200 mg — 112,327 bottles by our sum — initiated January 29, 2026. Both are Class II. Earlier, in August 2025, Westminster Pharmaceuticals recalled metoprolol tartrate 50 and 100 mg for “Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake.”

In the FDA’s terms, a recall is a company removing or correcting a product that violates the rules, ranked Class I to III by risk; a “market withdrawal” is reserved for minor violations. Most drug recalls are voluntary and are announced through the FDA’s weekly enforcement report, not through press releases, which is why many people first hear about them from news or from their pharmacy.

For the Amazon acetaminophen recall, the next step is the FDA’s classification, which will appear in a later enforcement report. We will update this page when the class is assigned, or if a refund program or lawsuit specific to these lots appears.